Encephalopathy after unintentional intrathecal gadolinium: A letter to the editor

• Published in: Interventional Pain Medicine (Online) 2022-09, Vol.1 (3), p.100105, Article 100105
• Main Authors: Moradian, Maxim, Tekmyster, Gene, Wei, Jason J., Avetisian, Henry, Acharya, Jayant N., Furman, Michael B.
• Format: Article
• Language: English
• Subjects: Letters to the Editor
• ISSN: 2772-5944; 2772-5944
• DOI: 10.1016/j.inpm.2022.100105

Raise awareness of gadolinium encephalopathy, a rare cause of neurological symptoms. An L5-S1 interlaminar epidural steroid injection (IL-ESI) was performed with a gadolinium-based contrast agent (GBCA) due to the patient's history of allergic reaction to iodine-based contrast agents. Several hours after administration of GBCA, the patient had nausea and vomiting with altered mental status. Patient was treated with dexamethasone IV, and was discharged on day 2. Patient had no residual deficits at follow-up two weeks later. Current literature shows that caution should be used to prevent inadvertent intrathecal GBCA, and doses >2.0 mmols are associated with serious adverse effects, including death. Intrathecal administration of GBCAs should be limited to less than 0.5 mmol. If adverse effects are experienced, IV steroids should be administered as soon as possible, and a CSF drain should be considered.